schliessen

Filtern

 

Bibliotheken

Adverse events following immunization with typhoid conjugate vaccine in an outbreak setting in Hyderabad, Pakistan

•Post licensure safety data of Typbar-TCV® is not available from a population wide campaign setting.•207,000 doses of Typbar-TCV were administered in a campaign setting of Hyderabad, Pakistan.•No death, disability or hospitalization associated with Typbar-TCV during 14 days of vaccination was observ... Full description

Journal Title: Vaccine 2020-04-23, Vol.38 (19), p.3518-3523
Main Author: Qamar, Farah Naz
Other Authors: Yousafzai, Mohammad Tahir , Khaliq, Asif , Karim, Sultan , memon, Hina , Junejo, Amber , Baig, Inayat , Rahman, Najeeb , Bhurgry, Shafqat , Afroz, Hina , Sami, Uzma
Format: Electronic Article Electronic Article
Language: English
Subjects:
Age
exp
Quelle: Alma/SFX Local Collection
Publisher: Netherlands: Elsevier Ltd
ID: ISSN: 0264-410X
Link: https://www.ncbi.nlm.nih.gov/pubmed/32201138
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7166079
title: Adverse events following immunization with typhoid conjugate vaccine in an outbreak setting in Hyderabad, Pakistan
format: Article
creator:
  • Qamar, Farah Naz
  • Yousafzai, Mohammad Tahir
  • Khaliq, Asif
  • Karim, Sultan
  • memon, Hina
  • Junejo, Amber
  • Baig, Inayat
  • Rahman, Najeeb
  • Bhurgry, Shafqat
  • Afroz, Hina
  • Sami, Uzma
subjects:
  • Adverse Drug Reaction Reporting Systems
  • Adverse events
  • adverse events following immunization
  • AEFI
  • AEFI, adverse events following immunization
  • Age
  • Article
  • Campaign
  • Child
  • Child, Preschool
  • Children
  • Children & youth
  • Collaboration
  • Conjugates
  • Data collection
  • DC, Deputy commissioner
  • Deputy commissioner
  • DG health
  • DG health, Director General Health
  • Diagnostic systems
  • diphtheria toxoid conjugated vi
  • Director General Health
  • Disease Outbreaks
  • Drug resistance
  • ed program on immunization
  • EPI, expanded program on immunization
  • ERC, ethical review committee
  • ethical review committee
  • exp
  • extensively drug resistant typhoid
  • Fever
  • GAVI, Global Alliance for Vaccine and Immunization
  • Global Alliance for Vaccine
  • Humans
  • Immunization
  • Infant
  • intravenous
  • IV, intravenous
  • MDR, Multi Drug Resistant
  • Multi Drug Resistant
  • National Bioethics committee
  • NBC, National Bioethics committee
  • Outbreaks
  • Pakistan
  • Parents
  • Parents & parenting
  • polysaccharide vaccine
  • S.Typhi, salmonella Typhi
  • Salmonella Typhi
  • SEAP, Surveillance of Enteric Fever in Asia Project
  • Surveillance
  • Surveillance of Enteric Fever in Asia Project
  • TCV, typhoid conjugate vaccine
  • Teams
  • Typbar
  • Typbar-TCV
  • Typhi
  • Typhoid
  • typhoid conjugate vaccine
  • Typhoid Fever - epidemiology
  • Typhoid Fever - prevention & control
  • Typhoid-Paratyphoid Vaccines - adverse effects
  • Vaccination
  • Vaccination - adverse effects
  • Vaccines
  • Vaccines, Conjugate
  • Vi capsular polysaccharide
  • Vi-DT, diphtheria toxoid conjugated vi-polysaccharide vaccine
  • ViCPS
  • ViCPS, Vi capsular polysaccharide
  • WHO, World Health Organization
  • World Health Organization
  • XDR, extensively drug resistant typhoid
ispartof: Vaccine, 2020-04-23, Vol.38 (19), p.3518-3523
description: •Post licensure safety data of Typbar-TCV® is not available from a population wide campaign setting.•207,000 doses of Typbar-TCV were administered in a campaign setting of Hyderabad, Pakistan.•No death, disability or hospitalization associated with Typbar-TCV during 14 days of vaccination was observed.•Fever and local reactogenicity were the frequently observed adverse events. Pakistan is facing the world's largest outbreak of extensively drug-resistant (XDR) Typhoid. Vaccination campaign for children aged 6 months to 10 years old with Typhoid Conjugate Vaccine (Typbar-TCV®) was conducted in high-risk areas of Hyderabad during 2018. About 207,000 children were vaccinated. Here we report the adverse events following immunization (AEFI) during the campaign. The campaign was carried out using outreach and fixed centre strategy. Community mobilizers visited each household to perform line listing and mobilize parents with age-eligible children. Children were observed for 30 min post-vaccination. Two-pronged strategy was used for ascertainment of AEFI. A 24/7 hotline number was provided to all parents/caretakers (n = 199,861) to report AEFI during 14 days following immunization. An age-stratified (n = 7139 children) were actively followed at days 7 and 14 for the ascertainment of AEFI. All AEFI were examined by three trained medical officers. A structured questionnaire using Brighton collaboration criteria with level 3 diagnostic certainty was used for the recording of AEFI. Data were analysed using Microsoft Excel Office 365. Overall, 499 AEFI (433 in the subset actively followed and 66 self-reported through hotline) were observed. The rate of AEFI was significantly higher among very young children (age group 6 to 12 months) as compared to 2 to 3 years old children (0.54% vs. 0.33% respectively; p-value 
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 0264-410X
fulltext: fulltext
issn:
  • 0264-410X
  • 1873-2518
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.616716
LOCALfalse
PrimoNMBib
record
control
sourceidproquest_pubme
recordidTN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7166079
sourceformatXML
sourcesystemPC
sourcerecordid2417039022
originalsourceidFETCH-LOGICAL-1510t-606f9678d49153ff58ce1f7715428f42a9a5eb357f3d4c5cd662e294a62c6c133
addsrcrecordideNqFUU2P0zAUjBCILQs_AWSJKwn-TnIBrVZAkVaCA0jcLNd-aZ1t7WI7WZVfj0vLij1xeoc3M-_NTFW9JLghmMi3YzNrY5yHhmKKG8waTLtH1YJ0LaupIN3jaoGp5DUn-MdF9SylEWMsGOmfVheMUkwI6xZVvLIzxAQIZvA5oSFst-HO-TVyu93k3S-dXfDozuUNyof9JjiLTPDjtNYZ0PkF5DzSHoUpryLoW5Qg5z8SHi0PFqJeafsGfdW3LmXtn1dPBr1N8OI8L6vvHz98u17WN18-fb6-uqmJIDjXEsuhl21neU8EGwbRGSBD2xLBaTdwqnstYMVEOzDLjTBWSgq051pSIw1h7LJ6d9LdT6sdWFP8Rb1V--h2Oh5U0E493Hi3Ueswq5ZIidu-CCxPAmEPXrsID7jWQ1bBKipbBZTzkijTghhqRMuwIFzyAbjuhBRHqdfnX2L4OUHKagxT9MW-opy0mPWY0oISJ5SJIaUIw_1BgtWxdTWqc-Tq2LrCTJXWC-_Vv07vWX9rLoD3JwCUvGcHUSXjwBuwxZXJygb3nxO_AYSxwO8
sourcetypeOpen Access Repository
isCDItrue
recordtypearticle
pqid2417039022
display
typearticle
titleAdverse events following immunization with typhoid conjugate vaccine in an outbreak setting in Hyderabad, Pakistan
sourceAlma/SFX Local Collection
creatorQamar, Farah Naz ; Yousafzai, Mohammad Tahir ; Khaliq, Asif ; Karim, Sultan ; memon, Hina ; Junejo, Amber ; Baig, Inayat ; Rahman, Najeeb ; Bhurgry, Shafqat ; Afroz, Hina ; Sami, Uzma
creatorcontribQamar, Farah Naz ; Yousafzai, Mohammad Tahir ; Khaliq, Asif ; Karim, Sultan ; memon, Hina ; Junejo, Amber ; Baig, Inayat ; Rahman, Najeeb ; Bhurgry, Shafqat ; Afroz, Hina ; Sami, Uzma
description•Post licensure safety data of Typbar-TCV® is not available from a population wide campaign setting.•207,000 doses of Typbar-TCV were administered in a campaign setting of Hyderabad, Pakistan.•No death, disability or hospitalization associated with Typbar-TCV during 14 days of vaccination was observed.•Fever and local reactogenicity were the frequently observed adverse events. Pakistan is facing the world's largest outbreak of extensively drug-resistant (XDR) Typhoid. Vaccination campaign for children aged 6 months to 10 years old with Typhoid Conjugate Vaccine (Typbar-TCV®) was conducted in high-risk areas of Hyderabad during 2018. About 207,000 children were vaccinated. Here we report the adverse events following immunization (AEFI) during the campaign. The campaign was carried out using outreach and fixed centre strategy. Community mobilizers visited each household to perform line listing and mobilize parents with age-eligible children. Children were observed for 30 min post-vaccination. Two-pronged strategy was used for ascertainment of AEFI. A 24/7 hotline number was provided to all parents/caretakers (n = 199,861) to report AEFI during 14 days following immunization. An age-stratified (n = 7139 children) were actively followed at days 7 and 14 for the ascertainment of AEFI. All AEFI were examined by three trained medical officers. A structured questionnaire using Brighton collaboration criteria with level 3 diagnostic certainty was used for the recording of AEFI. Data were analysed using Microsoft Excel Office 365. Overall, 499 AEFI (433 in the subset actively followed and 66 self-reported through hotline) were observed. The rate of AEFI was significantly higher among very young children (age group 6 to 12 months) as compared to 2 to 3 years old children (0.54% vs. 0.33% respectively; p-value < 0.001). Fever was the most common AEFI self-reported through the hotline (38/199,861 = 0.02%) and among the subset followed actively for 14 days (206/7139 = 2.89%). Fever was followed by local reactogenicity 10/199,861(0.01%), and 134/7139 (1.88%) through self-reported hotline and active follow-up, respectively. No serious AEFI was observed. Administration of a single dose of Typbar-TCV among children aged 6 months to 10 years old during an outbreak setting of Hyderabad Pakistan was safe.
identifier
0ISSN: 0264-410X
1EISSN: 1873-2518
2DOI: 10.1016/j.vaccine.2020.03.028
3PMID: 32201138
languageeng
publisherNetherlands: Elsevier Ltd
subjectAdverse Drug Reaction Reporting Systems ; Adverse events ; adverse events following immunization ; AEFI ; AEFI, adverse events following immunization ; Age ; Article ; Campaign ; Child ; Child, Preschool ; Children ; Children & youth ; Collaboration ; Conjugates ; Data collection ; DC, Deputy commissioner ; Deputy commissioner ; DG health ; DG health, Director General Health ; Diagnostic systems ; diphtheria toxoid conjugated vi ; Director General Health ; Disease Outbreaks ; Drug resistance ; ed program on immunization ; EPI, expanded program on immunization ; ERC, ethical review committee ; ethical review committee ; exp ; extensively drug resistant typhoid ; Fever ; GAVI, Global Alliance for Vaccine and Immunization ; Global Alliance for Vaccine ; Humans ; Immunization ; Infant ; intravenous ; IV, intravenous ; MDR, Multi Drug Resistant ; Multi Drug Resistant ; National Bioethics committee ; NBC, National Bioethics committee ; Outbreaks ; Pakistan ; Parents ; Parents & parenting ; polysaccharide vaccine ; S.Typhi, salmonella Typhi ; Salmonella Typhi ; SEAP, Surveillance of Enteric Fever in Asia Project ; Surveillance ; Surveillance of Enteric Fever in Asia Project ; TCV, typhoid conjugate vaccine ; Teams ; Typbar ; Typbar-TCV ; Typhi ; Typhoid ; typhoid conjugate vaccine ; Typhoid Fever - epidemiology ; Typhoid Fever - prevention & control ; Typhoid-Paratyphoid Vaccines - adverse effects ; Vaccination ; Vaccination - adverse effects ; Vaccines ; Vaccines, Conjugate ; Vi capsular polysaccharide ; Vi-DT, diphtheria toxoid conjugated vi-polysaccharide vaccine ; ViCPS ; ViCPS, Vi capsular polysaccharide ; WHO, World Health Organization ; World Health Organization ; XDR, extensively drug resistant typhoid
ispartofVaccine, 2020-04-23, Vol.38 (19), p.3518-3523
rights
02020 The Author(s)
1Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.
22020. The Author(s)
32020 The Author(s) 2020
lds50peer_reviewed
oafree_for_read
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32201138$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Qamar, Farah Naz
1Yousafzai, Mohammad Tahir
2Khaliq, Asif
3Karim, Sultan
4memon, Hina
5Junejo, Amber
6Baig, Inayat
7Rahman, Najeeb
8Bhurgry, Shafqat
9Afroz, Hina
10Sami, Uzma
title
0Adverse events following immunization with typhoid conjugate vaccine in an outbreak setting in Hyderabad, Pakistan
1Vaccine
addtitleVaccine
description•Post licensure safety data of Typbar-TCV® is not available from a population wide campaign setting.•207,000 doses of Typbar-TCV were administered in a campaign setting of Hyderabad, Pakistan.•No death, disability or hospitalization associated with Typbar-TCV during 14 days of vaccination was observed.•Fever and local reactogenicity were the frequently observed adverse events. Pakistan is facing the world's largest outbreak of extensively drug-resistant (XDR) Typhoid. Vaccination campaign for children aged 6 months to 10 years old with Typhoid Conjugate Vaccine (Typbar-TCV®) was conducted in high-risk areas of Hyderabad during 2018. About 207,000 children were vaccinated. Here we report the adverse events following immunization (AEFI) during the campaign. The campaign was carried out using outreach and fixed centre strategy. Community mobilizers visited each household to perform line listing and mobilize parents with age-eligible children. Children were observed for 30 min post-vaccination. Two-pronged strategy was used for ascertainment of AEFI. A 24/7 hotline number was provided to all parents/caretakers (n = 199,861) to report AEFI during 14 days following immunization. An age-stratified (n = 7139 children) were actively followed at days 7 and 14 for the ascertainment of AEFI. All AEFI were examined by three trained medical officers. A structured questionnaire using Brighton collaboration criteria with level 3 diagnostic certainty was used for the recording of AEFI. Data were analysed using Microsoft Excel Office 365. Overall, 499 AEFI (433 in the subset actively followed and 66 self-reported through hotline) were observed. The rate of AEFI was significantly higher among very young children (age group 6 to 12 months) as compared to 2 to 3 years old children (0.54% vs. 0.33% respectively; p-value < 0.001). Fever was the most common AEFI self-reported through the hotline (38/199,861 = 0.02%) and among the subset followed actively for 14 days (206/7139 = 2.89%). Fever was followed by local reactogenicity 10/199,861(0.01%), and 134/7139 (1.88%) through self-reported hotline and active follow-up, respectively. No serious AEFI was observed. Administration of a single dose of Typbar-TCV among children aged 6 months to 10 years old during an outbreak setting of Hyderabad Pakistan was safe.
subject
0Adverse Drug Reaction Reporting Systems
1Adverse events
2adverse events following immunization
3AEFI
4AEFI, adverse events following immunization
5Age
6Article
7Campaign
8Child
9Child, Preschool
10Children
11Children & youth
12Collaboration
13Conjugates
14Data collection
15DC, Deputy commissioner
16Deputy commissioner
17DG health
18DG health, Director General Health
19Diagnostic systems
20diphtheria toxoid conjugated vi
21Director General Health
22Disease Outbreaks
23Drug resistance
24ed program on immunization
25EPI, expanded program on immunization
26ERC, ethical review committee
27ethical review committee
28exp
29extensively drug resistant typhoid
30Fever
31GAVI, Global Alliance for Vaccine and Immunization
32Global Alliance for Vaccine
33Humans
34Immunization
35Infant
36intravenous
37IV, intravenous
38MDR, Multi Drug Resistant
39Multi Drug Resistant
40National Bioethics committee
41NBC, National Bioethics committee
42Outbreaks
43Pakistan
44Parents
45Parents & parenting
46polysaccharide vaccine
47S.Typhi, salmonella Typhi
48Salmonella Typhi
49SEAP, Surveillance of Enteric Fever in Asia Project
50Surveillance
51Surveillance of Enteric Fever in Asia Project
52TCV, typhoid conjugate vaccine
53Teams
54Typbar
55Typbar-TCV
56Typhi
57Typhoid
58typhoid conjugate vaccine
59Typhoid Fever - epidemiology
60Typhoid Fever - prevention & control
61Typhoid-Paratyphoid Vaccines - adverse effects
62Vaccination
63Vaccination - adverse effects
64Vaccines
65Vaccines, Conjugate
66Vi capsular polysaccharide
67Vi-DT, diphtheria toxoid conjugated vi-polysaccharide vaccine
68ViCPS
69ViCPS, Vi capsular polysaccharide
70WHO, World Health Organization
71World Health Organization
72XDR, extensively drug resistant typhoid
issn
00264-410X
11873-2518
fulltexttrue
rsrctypearticle
creationdate2020
recordtypearticle
recordideNqFUU2P0zAUjBCILQs_AWSJKwn-TnIBrVZAkVaCA0jcLNd-aZ1t7WI7WZVfj0vLij1xeoc3M-_NTFW9JLghmMi3YzNrY5yHhmKKG8waTLtH1YJ0LaupIN3jaoGp5DUn-MdF9SylEWMsGOmfVheMUkwI6xZVvLIzxAQIZvA5oSFst-HO-TVyu93k3S-dXfDozuUNyof9JjiLTPDjtNYZ0PkF5DzSHoUpryLoW5Qg5z8SHi0PFqJeafsGfdW3LmXtn1dPBr1N8OI8L6vvHz98u17WN18-fb6-uqmJIDjXEsuhl21neU8EGwbRGSBD2xLBaTdwqnstYMVEOzDLjTBWSgq051pSIw1h7LJ6d9LdT6sdWFP8Rb1V--h2Oh5U0E493Hi3Ueswq5ZIidu-CCxPAmEPXrsID7jWQ1bBKipbBZTzkijTghhqRMuwIFzyAbjuhBRHqdfnX2L4OUHKagxT9MW-opy0mPWY0oISJ5SJIaUIw_1BgtWxdTWqc-Tq2LrCTJXWC-_Vv07vWX9rLoD3JwCUvGcHUSXjwBuwxZXJygb3nxO_AYSxwO8
startdate20200423
enddate20200423
creator
0Qamar, Farah Naz
1Yousafzai, Mohammad Tahir
2Khaliq, Asif
3Karim, Sultan
4memon, Hina
5Junejo, Amber
6Baig, Inayat
7Rahman, Najeeb
8Bhurgry, Shafqat
9Afroz, Hina
10Sami, Uzma
general
0Elsevier Ltd
1Elsevier Limited
2Elsevier Science
scope
06I.
1AAFTH
2CGR
3CUY
4CVF
5ECM
6EIF
7NPM
8AAYXX
9CITATION
103V.
117QL
127RV
137T2
147T5
157U9
167X7
177XB
1888C
1988E
208AO
218C1
228FE
238FH
248FI
258FJ
268FK
278G5
28ABUWG
29AZQEC
30BBNVY
31BENPR
32BHPHI
33C1K
34DWQXO
35FYUFA
36GHDGH
37GNUQQ
38GUQSH
39H94
40HCIFZ
41K9-
42K9.
43KB0
44LK8
45M0R
46M0S
47M0T
48M1P
49M2O
50M7N
51M7P
52MBDVC
53NAPCQ
54PQEST
55PQQKQ
56PQUKI
57Q9U
58BOBZL
59CLFQK
605PM
sort
creationdate20200423
titleAdverse events following immunization with typhoid conjugate vaccine in an outbreak setting in Hyderabad, Pakistan
authorQamar, Farah Naz ; Yousafzai, Mohammad Tahir ; Khaliq, Asif ; Karim, Sultan ; memon, Hina ; Junejo, Amber ; Baig, Inayat ; Rahman, Najeeb ; Bhurgry, Shafqat ; Afroz, Hina ; Sami, Uzma
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-1510t-606f9678d49153ff58ce1f7715428f42a9a5eb357f3d4c5cd662e294a62c6c133
rsrctypearticles
prefilterarticles
languageeng
creationdate2020
topic
0Adverse Drug Reaction Reporting Systems
1Adverse events
2adverse events following immunization
3AEFI
4AEFI, adverse events following immunization
5Age
6Article
7Campaign
8Child
9Child, Preschool
10Children
11Children & youth
12Collaboration
13Conjugates
14Data collection
15DC, Deputy commissioner
16Deputy commissioner
17DG health
18DG health, Director General Health
19Diagnostic systems
20diphtheria toxoid conjugated vi
21Director General Health
22Disease Outbreaks
23Drug resistance
24ed program on immunization
25EPI, expanded program on immunization
26ERC, ethical review committee
27ethical review committee
28exp
29extensively drug resistant typhoid
30Fever
31GAVI, Global Alliance for Vaccine and Immunization
32Global Alliance for Vaccine
33Humans
34Immunization
35Infant
36intravenous
37IV, intravenous
38MDR, Multi Drug Resistant
39Multi Drug Resistant
40National Bioethics committee
41NBC, National Bioethics committee
42Outbreaks
43Pakistan
44Parents
45Parents & parenting
46polysaccharide vaccine
47S.Typhi, salmonella Typhi
48Salmonella Typhi
49SEAP, Surveillance of Enteric Fever in Asia Project
50Surveillance
51Surveillance of Enteric Fever in Asia Project
52TCV, typhoid conjugate vaccine
53Teams
54Typbar
55Typbar-TCV
56Typhi
57Typhoid
58typhoid conjugate vaccine
59Typhoid Fever - epidemiology
60Typhoid Fever - prevention & control
61Typhoid-Paratyphoid Vaccines - adverse effects
62Vaccination
63Vaccination - adverse effects
64Vaccines
65Vaccines, Conjugate
66Vi capsular polysaccharide
67Vi-DT, diphtheria toxoid conjugated vi-polysaccharide vaccine
68ViCPS
69ViCPS, Vi capsular polysaccharide
70WHO, World Health Organization
71World Health Organization
72XDR, extensively drug resistant typhoid
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Qamar, Farah Naz
1Yousafzai, Mohammad Tahir
2Khaliq, Asif
3Karim, Sultan
4memon, Hina
5Junejo, Amber
6Baig, Inayat
7Rahman, Najeeb
8Bhurgry, Shafqat
9Afroz, Hina
10Sami, Uzma
collection
0ScienceDirect Open Access Titles
1Elsevier:ScienceDirect:Open Access
2Medline
3MEDLINE
4MEDLINE (Ovid)
5MEDLINE
6MEDLINE
7PubMed
8CrossRef
9ProQuest Central (Corporate)
10Bacteriology Abstracts (Microbiology B)
11Nursing & Allied Health Database
12Health and Safety Science Abstracts (Full archive)
13Immunology Abstracts
14Virology and AIDS Abstracts
15Health & Medical Collection
16ProQuest Central (purchase pre-March 2016)
17Healthcare Administration Database (Alumni)
18Medical Database (Alumni Edition)
19ProQuest Pharma Collection
20Public Health Database
21ProQuest SciTech Collection
22ProQuest Natural Science Collection
23Hospital Premium Collection
24Hospital Premium Collection (Alumni Edition)
25ProQuest Central (Alumni) (purchase pre-March 2016)
26Research Library (Alumni Edition)
27ProQuest Central (Alumni Edition)
28ProQuest Central Essentials
29Biological Science Collection
30ProQuest Central
31Natural Science Collection
32Environmental Sciences and Pollution Management
33ProQuest Central Korea
34Health Research Premium Collection
35Health Research Premium Collection (Alumni)
36ProQuest Central Student
37Research Library Prep
38AIDS and Cancer Research Abstracts
39SciTech Premium Collection
40Consumer Health Database (Alumni Edition)
41ProQuest Health & Medical Complete (Alumni)
42Nursing & Allied Health Database (Alumni Edition)
43ProQuest Biological Science Collection
44Consumer Health Database
45Health & Medical Collection (Alumni Edition)
46Healthcare Administration Database
47Medical Database
48Research Library
49Algology Mycology and Protozoology Abstracts (Microbiology C)
50Biological Science Database
51Research Library (Corporate)
52Nursing & Allied Health Premium
53ProQuest One Academic Eastern Edition
54ProQuest One Academic
55ProQuest One Academic UKI Edition
56ProQuest Central Basic
57OpenAIRE (Open Access)
58OpenAIRE
59PubMed Central (Full Participant titles)
jtitleVaccine
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Qamar, Farah Naz
1Yousafzai, Mohammad Tahir
2Khaliq, Asif
3Karim, Sultan
4memon, Hina
5Junejo, Amber
6Baig, Inayat
7Rahman, Najeeb
8Bhurgry, Shafqat
9Afroz, Hina
10Sami, Uzma
formatjournal
genrearticle
ristypeJOUR
atitleAdverse events following immunization with typhoid conjugate vaccine in an outbreak setting in Hyderabad, Pakistan
jtitleVaccine
addtitleVaccine
date2020-04-23
risdate2020
volume38
issue19
spage3518
epage3523
pages3518-3523
issn0264-410X
eissn1873-2518
notes
0Both authors equally contributed.
1Co-first authors.
abstract•Post licensure safety data of Typbar-TCV® is not available from a population wide campaign setting.•207,000 doses of Typbar-TCV were administered in a campaign setting of Hyderabad, Pakistan.•No death, disability or hospitalization associated with Typbar-TCV during 14 days of vaccination was observed.•Fever and local reactogenicity were the frequently observed adverse events. Pakistan is facing the world's largest outbreak of extensively drug-resistant (XDR) Typhoid. Vaccination campaign for children aged 6 months to 10 years old with Typhoid Conjugate Vaccine (Typbar-TCV®) was conducted in high-risk areas of Hyderabad during 2018. About 207,000 children were vaccinated. Here we report the adverse events following immunization (AEFI) during the campaign. The campaign was carried out using outreach and fixed centre strategy. Community mobilizers visited each household to perform line listing and mobilize parents with age-eligible children. Children were observed for 30 min post-vaccination. Two-pronged strategy was used for ascertainment of AEFI. A 24/7 hotline number was provided to all parents/caretakers (n = 199,861) to report AEFI during 14 days following immunization. An age-stratified (n = 7139 children) were actively followed at days 7 and 14 for the ascertainment of AEFI. All AEFI were examined by three trained medical officers. A structured questionnaire using Brighton collaboration criteria with level 3 diagnostic certainty was used for the recording of AEFI. Data were analysed using Microsoft Excel Office 365. Overall, 499 AEFI (433 in the subset actively followed and 66 self-reported through hotline) were observed. The rate of AEFI was significantly higher among very young children (age group 6 to 12 months) as compared to 2 to 3 years old children (0.54% vs. 0.33% respectively; p-value < 0.001). Fever was the most common AEFI self-reported through the hotline (38/199,861 = 0.02%) and among the subset followed actively for 14 days (206/7139 = 2.89%). Fever was followed by local reactogenicity 10/199,861(0.01%), and 134/7139 (1.88%) through self-reported hotline and active follow-up, respectively. No serious AEFI was observed. Administration of a single dose of Typbar-TCV among children aged 6 months to 10 years old during an outbreak setting of Hyderabad Pakistan was safe.
copNetherlands
pubElsevier Ltd
pmid32201138
doi10.1016/j.vaccine.2020.03.028
oafree_for_read